#1 Clinical Trials Search in Europe

Ttx-030

Ttx-030 has been studied in clinical trials for people with metastatic pancreatic adenocarcinoma who had not received prior treatment. These trials look at whether adding Ttx-030, with or without budigalimab, to chemotherapy can improve outcomes such as progression-free survival and assess safety.

Table of Contents

Trial overview

The main clinical trial for Ttx-030 in the source data was an open-label, multicenter, randomized Phase 2 study in people with metastatic pancreatic adenocarcinoma who had not been treated before.[1]

This trial was designed to assess the efficacy and safety of Ttx-030 added to chemotherapy, with or without budigalimab, compared with chemotherapy alone.[1]

Who was studied

The trial focused on patients with metastatic pancreatic adenocarcinoma, which means pancreatic cancer that had spread to other parts of the body.[1]

It studied people who were not previously treated for this cancer, so the results apply to patients starting treatment for the first time in this setting.[1]

Treatments compared

The study had three treatment groups: chemotherapy alone, chemotherapy plus Ttx-030, and chemotherapy plus Ttx-030 with budigalimab.[1]

The chemotherapy backbone in the trial was nab-paclitaxel plus gemcitabine, which were given by intravenous infusion.[1]

Budigalimab was included in one of the study arms, so the trial also looked at whether adding this extra treatment changed the results compared with the other groups.[1]

What was measured

The main outcome was progression-free survival (PFS), which is the length of time a patient lives without the cancer getting worse.[1]

This endpoint helps researchers see whether the study treatment may delay cancer growth or spread compared with the control group.[1]

The trial also aimed to assess safety, which means it looked at how well patients tolerated the treatment in the study setting.[1]

Trial status and size

The trial was completed and enrolled 173 participants.[1]

Because it was a multicenter study, the trial was carried out at more than one site, which can help include a broader group of patients and make the results more useful in practice.[1]

What this means for patients

Based on the source data, Ttx-030 has been tested as part of a treatment plan for people with advanced pancreatic cancer who had not received prior therapy.[1]

The study was built to compare different treatment combinations, so it can help researchers understand whether adding Ttx-030, with or without budigalimab, may improve the time before the cancer gets worse.[1]

Trial IDPhaseCondition studiedStatusEnrollment
NCT06119217Phase 2Metastatic pancreatic adenocarcinomaCompleted173

FAQ

  • What is being studied in the Ttx-030 trials? The trial is studying Ttx-030 added to chemotherapy, with or without budigalimab, compared with chemotherapy alone. The main goal is to see if the combination helps people with metastatic pancreatic adenocarcinoma.
  • Who could take part in the trial? The trial focused on patients with metastatic pancreatic adenocarcinoma who had not been treated before. This means it studied people with cancer that had spread to other parts of the body and who were starting treatment.
  • What phase was the trial? This was a Phase 2 trial. Phase 2 studies usually look more closely at whether a treatment seems to work and continue checking safety.
  • What treatment groups were compared? The study compared three groups: chemotherapy alone, chemotherapy plus Ttx-030, and chemotherapy plus Ttx-030 with budigalimab. This helps show whether adding one or both study drugs changes the results.
  • What outcome was the trial mainly measuring? The main outcome was progression-free survival, often called PFS. This means the study measured how long patients lived without their cancer getting worse.

Ongoing Clinical Trials on Ttx-030

  • Study on TTX-030, Budigalimab, and Chemotherapy for Untreated Metastatic Pancreatic Cancer Patients

    Not recruiting

    2 1 1 1
    Investigated drugs:
    Czechia France Italy Spain

Glossary

  • Metastatic pancreatic adenocarcinoma: A type of pancreatic cancer that has spread from the pancreas to other parts of the body.
  • Adenocarcinoma: A cancer that starts in gland-like cells, which make and release fluids.
  • Phase 2: A trial stage that looks at whether a treatment may work and continues to assess safety in a larger group of patients.
  • Interventional study: A study where participants receive one or more treatments so researchers can compare results.
  • Randomized: Participants are placed into treatment groups by chance, which helps make the comparison fair.
  • Open-label: A study design where both the researchers and participants know which treatment is being given.
  • Multicenter: A trial carried out at more than one hospital or clinic.
  • Chemotherapy: Cancer treatment that uses drugs to kill cancer cells or stop them from growing.
  • Progression-free survival (PFS): The length of time during and after treatment that a cancer does not get worse.
  • Enrollment: The number of people who joined the study.
  • Primary outcome: The main result the researchers planned to measure in the trial.

References